← All companies
BridgeBio Pharma, Inc.
BBIO - CIK 0001743881
Market cap$13.20 B
Rank#791
SEC filings777
BridgeBio Pharma, Inc. trades as BBIO and has a market capitalization of $13.20 B, making it the #791 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $502.08M, up 126.3% from the prior year. This page tracks BridgeBio Pharma, Inc. through 777 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$502.08MFY 2025
Operating cash flow (latest FY)-$445.91MFY 2025
Total assets (latest FY)$936.02MFY 2025
Financial performance
Over the last 6 fiscal years BridgeBio Pharma, Inc.'s revenue grew from $40.56M to $502.08M, a compound annual growth rate of 52.1%.
Key statistics
- Market cap
- $13.20 B
- Share price (derived)market cap / shares outstanding
- $67.40
- EPS (diluted)FY 2025
- $-3.78
- Shares outstandingas of 2026-04-30
- 0.20B
- Long-term debtas of 2026-03-31
- $2.65B
- Cash & equivalentsas of 2026-03-31
- $879.89M
- Dividends paidFY 2019
- $997.00K
- Stock buybacksFY 2025
- $48.28M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-21 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
Recent press releases
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH12026-05-12
_\- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1_
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure2026-05-11
_-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM_
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)2026-05-08
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit **bridgebio.com** and follow us on **LinkedIn**, **X**, **Facebook**, **Instagram**, **YouTube**, and **TikTok** **.**
- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates2026-05-07
Similar companies
The largest companies sharing BridgeBio Pharma, Inc.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is BridgeBio Pharma, Inc.'s market cap?
BridgeBio Pharma, Inc. (BBIO) has a market capitalization of $13.20 B as of 2026-06-10, ranking #791 among US-listed companies.
How much revenue does BridgeBio Pharma, Inc. make?
BridgeBio Pharma, Inc. reported revenue of $502.08M for fiscal year 2025, an increase of 126.3% year over year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.